Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research note issued to investors on Tuesday. They currently have a $33.00 target price on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 105.61% from the company’s previous close. Several other brokerages have also […]
